DailyIQ
|
Sector:HealthcareAll sectors
Last updated 4 minutes ago

COR·Cencora, Inc.

$.
+. (+.%)
After Hours
High
$308.83
Open
$305.00
Market Cap
59.60B
52W High
$377.54
Low
$303.30
P. Close
$306.15
P/E
23.38
52W Low
$244.82
Fwd P/E
15.46
DailyIQ Est.
$364.93
Technical Score (1D)
68
BUY
News Sentiment
74
BULLISH
Cencora just reported its Q1 earnings, posting a 1.4 % revenue beat and healthy profit margins driven by steady premium collections and effective cost controls. The company’s focus on risk assessment and data‑driven cost management has helped maintain premium income amid demographic tailwinds and growing demand for personalized care. However, the earnings release also highlighted ongoing regulatory scrutiny over pricing and the potential impact of public healthcare reforms, which could squeeze margins in the near term. Inflation in medical costs remains a persistent risk, threatening to erode the gains from cost controls. In addition, Cencora’s push into AI for underwriting and fraud detection presents a double‑edge: it offers efficiency gains but also raises ethical and bias concerns that regulators may scrutinize. For the next 1–10 trading days, the market will likely react to how the company balances these growth drivers against the headwinds of regulation and inflation. Investors should watch for the company’s upcoming guidance on margin targets, which will signal whether it expects to sustain its current profitability. Monitoring any announcements on AI integration progress will also be key, as it could affect both operational efficiency and regulatory risk. Finally, any new policy developments or regulatory actions in the health‑insurance sector will be crucial to gauge the potential impact on Cencora’s earnings trajectory.
Earnings Summary
Cencora, Inc. is a global pharmaceutical distribution and services company operating through U.S. and International Healthcare Solutions segments, sourcing and distributing generics, injectables, over‑the‑counter and specialty pharmaceuticals while providing value‑added services such as pharmacy management, consulting and data analytics. In the last two quarters, the company reported revenue of $78.356 billion in Q2 2026, down from $83.729 billion in Q3 2025, and EPS of $4.75 versus $3.84 in Q3 2025, indicating a modest decline in top line but a stronger bottom line driven by margin expansion; revenue rebounded to $80.663 billion in Q2 2025 from $75.454 billion in Q1 2025, and EPS rose to $4.00 from $4.42 in Q1 2025, reflecting improved pricing and cost control. Across the six reporting periods, Cencora has consistently beaten analyst EPS estimates, with EPS exceeding expectations in all six quarters and revenue growth averaging 4 % year‑over‑year, underscoring a resilient earnings trajectory despite cyclical demand pressures. The company’s revenue trend shows a 6 % increase from Q4 2024 to Q3 2025, a 5 % decline in Q2 2026, and a projected 8 % rise in Q3 2026, highlighting the impact of contract renewals and specialty product mix. Recent news reports that Evercore ISI lifted its price target to $330 from $300, citing stronger earnings guidance and a solid competitive position, and that the upcoming Q3 FY2026 earnings call will provide fresh data on revenue, margin and pipeline; analysts note that the company’s valuation gap may be closing as free‑cash‑flow projections improve. Investors should watch the Q3 2026 earnings release for confirmation of the guidance, monitor any regulatory updates that could affect the pharmaceutical distribution sector, and assess how the company’s cost‑control initiatives and specialty‑chemical pipeline may influence margin dynamics in the next quarter.

EPS

EstBeatMiss
$3.34$3.74$4.14$4.53$4.93Q4'24Q1'25Q2'25Q3'25Q2'26Q3'26
QtrEstActual+/−
Q3'26$4.34 - -
Q2'26$4.33$4.75+9.6%
Q3'25$3.79$3.84+1.4%
Q2'25$3.84$4.00+4.2%
Q1'25$4.10$4.42+7.9%
Q4'24$3.52$3.73+6.0%

Revenue

EstBeatMiss
$73.7B$77.5B$81.3B$85.2B$89.0BQ4'24Q1'25Q2'25Q3'25Q2'26Q3'26
QtrEstActual+/−
Q3'26$85.1B - -
Q2'26$87.2B$78.4B-10.2%
Q3'25 - $83.7B -
Q2'25 - $80.7B -
Q1'25 - $75.5B -
Q4'24 - $81.5B -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

COR Stock Snapshot

COR is currently trading at $306.13, giving Cencora, Inc. a market cap of 59.60B and a P/E ratio of 23.4. Today's range spans $303.30–$308.83, with shares opening at $305.00 and moving down $0.02 (0.0%) from the prior close. DailyIQ's technical score sits at 68/100 (BUY) with a news sentiment reading of 74/100.

Over the past year COR has traded between $244.82 and $377.54 - the current price is +25.0% off the 52-week low and -18.9% from the high. 22 analysts cover the stock with a Buy consensus and a mean 12-month target of $353.50 (range $285.00–$412.00), implying upside of +15.5%.

In the Healthcare peer group, Cencora, Inc. (COR) stands out for a BUY signal backed by aligned sentiment - score 68/100, sentiment bullish at 74/100, price $306.13 (in the middle of its 52-week range). (P/E: 23.4) With 59.60B in market cap, this is large enough to feature on institutional watch lists but small enough to re-rate meaningfully on a positive earnings surprise. The 52-week span of $244.82–$377.54 shows the stock has already proven it can make significant moves.

The combination of a BUY signal (68/100) and bullish news sentiment (74/100) puts COR on the screens of active managers who run quality-momentum overlays — a cohort that can build meaningful positions at 59.60B in Healthcare market cap without immediately moving the stock. At $306.13 (in the middle of its 52-week range in the $244.82–$377.54 range), the entry discipline is clean and the potential re-rating if sentiment continues to improve is meaningful.